Sector News

Pfizer to look for 20% cost cuts in some manufacturing

April 8, 2016
Life sciences

Having deep-sixed its $160 billion merger with Allergan, and the tax savings the inversion deal had promised, Pfizer is already looking at ways to cut costs. Manufacturing looks to be one area where it hopes to cut costs by 20% on some key products in coming years.

That is the message given to employees at Pfizer’s plants in Little Island and Ringaskiddy in Cork County, Ireland, the Irish Examiner reports. The plants make the API for Lipitor and other drugs. The site has already cut costs an average of 34% at the two plants in recent years, improvements that helped the Little Island facility avoid Pfizer’s earlier decision to shutter it.

Seamus Fives, who oversees the two facilities, told the Examiner that the plant employees had “stopped the rot” at the operations but would need to remain focused on efficiency and redouble efforts to be competitive.

The observation followed the decision announced Wednesday by Pfizer and Allergan to cancel their tax inversion-based merger after the U.S. Treasury rolled out even more new rules, specifically targeted at stopping it. The inversion would have cut Pfizer’s U.S. tax bill significantly because it planned on taking on Allergan’s domicile in Ireland, a low-tax country, while its management could have remained ensconced in New York. This deal, and others like it, have been criticized by some politicians and others for being nothing but tax dodges.

The employees in Cork are already steeped in the vicissitudes of the pharma world. The drugmaker announced its plan to consolidate its manufacturing in Ireland in May 2013, expecting to be fully out of the Little Island plant by August 2014. However, due to the efficiency improvements and “unexpected increase” in Lipitor demand, Pfizer postponed the closure and then canceled it last year. The facility, helped by sales strength of a couple of cancer drugs for which it makes the APIs, actually added employees late last year.

By Eric Palmer

Source: Fierce Pharma Manufacturing

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach